Tofacitinib 2% for the Treatment of Refractory Vitiligo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Open-Label Pilot Study of Tofacitinib 2% for the Treatment of Refractory Vitiligo
Br J Dermatol 2019 Oct 12;[EPub Ahead of Print], P Mobasher, R Guerra, SJ Li, J Frangos, AK Ganesan, V HuangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.